As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.

Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.

Scrip takes a look at how the South Korean pharma/biotech industry's cross-border deals over the past few years compare with global trends, finding that oncology and diabetes have been the dominant therapeutic areas for the out-licensing of assets, but recent activity and value have declined from a peak in 2015.